H3-DYNAMICS
16.1.2023 16:08:41 CET | Business Wire | Press release
H3 Dynamics and Hylium Industries have joined forces to boost the performance of zero emission hydrogen-electric flight, by combining the strengths of Hylium’s liquid hydrogen storage and liquification solutions, and H3 Dynamics’ distributed hydrogen-electric propulsion nacelles, ultra-light fuel cells, and new hydrogen drone refueling stations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230116005162/en/
Joint development for transatlantic crossing with ISAE-SUPAERO Toulouse, H3 Dynamics - using HYLIUM Liquid hydrogen storage (Photo: Business Wire)
Moving to liquid hydrogen represents a significant capability leap for small electric-powered unmanned systems. Cryogenic (liquid) hydrogen stores 3 times more energy as compressed gas in the same given volume. This means delivery drones will be able to fly further, mapping and ISR missions could be done on a much bigger scale.
To illustrate the jump in performance, the same 25kg hydrogen-electric propulsion UAV demonstrated by H3 Dynamics last July in France, will be able to fly over 900km with a single fill. With pressurized hydrogen, that range reduces to 400km, which is still 3 times more than a battery-powered equivalent.
“When combined, our global best-in-class solutions achieve the global performance limit for low-altitude electric powered flight” says Taras Wankewycz, CEO H3 Dynamics. “We are proud to be working with Hylium to move hydrogen-electric flight propulsion to the next level”
Now all the various forms of hydogen drones and UAVs powered by H3 Dynamics including hydrogen airships, multi-rotors, vertical take-off and landing (VTOL), have a way to further boost flight durations by another factor of 3 over pressurized hydrogen systems, or a factor of 10 compared to batteries.
H3 Dynamics also recently announced a first hydrogen production, and automated hydrogen refueling mobile station for hydrogen UAV operations. Named H2FIELD the mobile station produces hydrogen from water and delivers compressed hydrogen gas tanks to the operator with little human intervention and no required hydrogen expertise. H3 Dynamics and Hylium’s partnership will upgrade the station so that it can fill liquid hydrogen tanks.
Developed in South Korea, Hylium’s breakthrough technology provides one of the most advanced solutions and has already been proven in a number of applications. South Korea is also leading the development for LH2 standardisation. One local proposal was accepted as a draft standard by a global ISO committee.
Hylium and H3 Dynamics technologies are currently being integrated to attempt a 3,300km crossing of the South Atlantic, in a program led by ISAE SUPAERO Toulouse, one of the world’s leading aerospace engineering schools. H3 Dynamics’ team developed a special fuselage design that can store a small LH2 tank and manage the thermal behavior of all the propulsion sub-systems.
LH2 technology will also be a next step in H3 Dynamics’ hydrogen-electric propulsor nacelles roadmap. A first twin engine cargo drone powered by these self-contained nacelles took off in the sky of Paris during the summer 2022, using 2 compressed hydrogen tanks – one in each nacelle. The goal now will be to switch them out for liquid hydrogen tanks with a lighter construction and a higher fuel capacity.
About H3 Dynamics www.h3dynamics.com
H3 Dynamics is on a mission to decarbonize aviation with a unique technology solution around distributed hydrogen-electric propulsion, as well as hydrogen refueling and airport power solutions. The company has created a unique pathway to de-risk long term hydrogen aviation developments by starting commercially now with small, scalable solutions. H3 Dynamics employs 93 team members from its 3 regional headquarters in Toulouse, Austin and Singapore. It is a member of the Alliance for Zero Emission Aviation under the European Commission, Sustainable Aero Lab, the Lufthansa Cleantech Hub, the Paris Advanced Air Mobility Alliance, and Aerospace Valley in Toulouse.
About Hylium Industries: http://hylium-industries.com/
HYLIUM INDUSTRIES, INC. was established in 2014 as a Korea Institute of Science and Technology (KIST) venture company. Since then Hylium have been developing the Korea’s first cryogenic liquid hydrogen manufacturing and storage technologies with R&D support from the Korean Government.
Hylium has developed various technologies related to the hydrogen liquefaction system and owns over 20 patents and intellectual property rights, with more patents pending. In 2015 Hylium Industries’ technologies were acknowledged by the Cryogenic Engineering Conference with a Russel B. Scott Memorial Award for the Best Application in Small-Capacity Hydrogen Liquefaction Technology.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005162/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom